Ierland - Engels - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - suspension for injection - 100 iu/ml - insulins and analogues for injection, intermediate- or long-acting combined with fast-acting - humulin m3 - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Ierland - Engels - HPRA (Health Products Regulatory Authority)

eli lilly and company limited - human insulin (recombinant dna origin) - solution for injection - 100 iu/ml - insulins and analogues for injection, fast-acting - humulin s - for the treatment of patients with diabetes mellitus who require insulin for the maintenance of glucose homeostasis

Verenigde Staten - Engels - NLM (National Library of Medicine)

gilead sciences, inc. - idelalisib (unii: yg57i8t5m0) (idelalisib - unii:yg57i8t5m0) - idelalisib 100 mg - zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. limitations of use zydelig is not indicated and is not recommended for first-line treatment of any patient, including patients with cll, small lymphocytic lymphoma (sll), follicular lymphoma (fl), and other indolent non-hodgkin lymphomas. zydelig is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with fl, sll, and other indolent non-hodgkin lymphomas. zydelig is contraindicated in patients with a history of serious hypersensitivity reactions to idelalisib, including anaphylaxis, or patients with a history of toxic epidermal necrolysis with any drug [see warnings and precautions (5.6, 5.7)] . risk summary based on findings in animal studies and the mechanism of action [see clinical pharmac

Australië - Engels - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nafarelin, quantity: 2 mg/ml - spray, solution - excipient ingredients: benzalkonium chloride; sorbitol; glacial acetic acid; hydrochloric acid; purified water; sodium hydroxide - indications as at 31 august 1995. synarel is indicated for the hormonal management of visually proven endometriosis, including pain relief and reduction of endometriotic lesions and for use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist.

Europese Unie - Engels - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine - anxiety disorders; diabetic neuropathies; depressive disorder, major - psychoanaleptics, - treatment of major depressive disorder.treatment of diabetic peripheral neuropathic pain.treatment of generalised anxiety disorder.cymbalta is indicated in adults.

Europese Unie - Engels - EMA (European Medicines Agency)

eli lilly and company limited  - fentanyl - nervous system - dogs - for the control of pain associated with orthopaedic and soft tissue surgery in dogs.

Europese Unie - Engels - EMA (European Medicines Agency)

eli lilly nederland b.v. - olaratumab - sarcoma - antineoplastic agents - lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).

Europese Unie - Engels - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloxetine hydrochloride - urinary incontinence, stress - psychoanaleptics, - yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (sui).

Europese Unie - Engels - EMA (European Medicines Agency)

eli lilly nederland b.v. - raloxifene hydrochloride - osteoporosis, postmenopausal - sex hormones and modulators of the genital system, - optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. a significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. when determining the choice of optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1).

Europese Unie - Engels - EMA (European Medicines Agency)

eli lilly nederland b.v. - lasmiditan succinate - migraine disorders - analgesics - rayvow is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.